Details for Human Fibrinogen ELISA Quantitation Kit
|Sample Type||Plasma. For the quantitative determination of human Fibrinogen levels in plasma. Blood, Vascular Diseases, Pathologic Processes, Blood Cells, Hematologic Diseases.|
|Product Name||Human Fibrinogen.|
|# of Samples||10X96 wells|
|Storage and Stability||-20°C|
|Range of Detection||6.25-400ng/mL|
|Shelf life||One year from date of receipt.|
|Assay Condition||The kit performance has been optimized for the protocol and materials listed below usingstandard dilutions of human Fibrinogen in the 6.25-400ng/mL range. The operator must determineappropriate dilutions of reagents for alternative assay conditions. ELISA assay reactivity is sensitive tovariations in operator, pipetting and washing techniques, incubation time, temperature, composition ofreagents, and other experimental variables. Assay optimization may be required to generate the standardcurve and fit the samples in the specified detection range.|
|Country of Origin||United States of America.|
|Assay Use||For Research Use Only (RUO). Not for diagnostic or therapeutic use in humans oranimals. Not for animal or human consumption.|
|Function||Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.|
|Subunit||Heterohexamer; disulfide linked. Contains 2 sets of 3 non-identical chains (alpha, beta and gamma). The 2 heterotrimers are in head to head conformation with the N-termini in a small central domain.|
|Domain||A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.|
|Ptm||The alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
|Disease||Defects in FGA are a cause of congenital afibrinogenemia [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. The majority of cases of afibrinogenemia are due to truncating mutations.
Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidois type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
|Similarity||Contains 1 fibrinogen C-terminal domain.|
Additional Info for Human Fibrinogen ELISA Quantitation Kit
|Name||Human Fibrinogen ELISA Quantitation Kit|
|Related Product Names||Human Fibrinogen ELISA Kit; N/A Human FibrinogenFGA|
|NCBI Acc Number||NP_000499.1|
|Swiss Prot Number||P02671|